Replay available

Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call

Outlook Therapeutics, Inc. (NASDAQ: OTLK) Q2 2024 earnings conference call, held 2024-05-16. Replay captured from the company's public earnings webcast.

Thu, May 16, 2024 at 8:30 AMendedReplay
Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Janine Thomas

Investor Relations

Russell Trenary

President and Chief Executive Officer

Lawrence Kenyon

Chief Financial Officer

Julian Harrison

Analyst, BTIG

Eddie Hickman

Analyst, Guggenheim Securities

Douglas Schauer

Analyst, H.C. Wainwright

Tim Chang

Analyst, Capital One

Kemp Dolliver

Analyst, Brookline Capital Markets

Ed Wu

Analyst, Ascendant Capital Markets

Daniil Gitalin

Analyst, Chardan

Replay transcript excerpt

Hello and welcome to the Outlook Therapeutics inaugural quarterly update conference call and webcast. As a brief reminder, all participants are currently in a listen-only mode. If anyone requires operator assistance during the event, please press star zero on your telephone keypad. Following the presentation, there will be a question and answer session. Note that this webcast is being recorded at the company's request and a replay will be made available on the company's website following the end of the event. It is now my pleasure to turn the call over to Janine Thomas of Investor Relations. Thank you, Daryl. At this time, I would like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations, or future projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws and are based on Outlook Therapeutics' current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the Outlook Therapeutics Annual Report on Form 10-K for the fiscal year ended September 30, 2023, and in other reports and files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Additionally, certain information contained in this webcast relates to or is based on studies, publications, survey...

More from Outlook Therapeutics, Inc.